Evidence map›Paper›PMID 38576342›Full record

ArticleJournal of gynecologic oncology2024

Patient and clinician priorities for information on treatment outcomes for advanced ovarian cancer: a Delphi exercise.

Kathryn Baxter, Heather Agnew, Jennie Morgan, Cathrine Holland, Darren Flynn, Richard Edmondson

Abstract read
In one paragraph

Article in Journal of gynecologic oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Kathryn BaxterDivision of Cancer Sciences, University of Manchester, Manchester, United Kingdom.ORCID 0000-0001-7359-0038
Heather AgnewDivision of Cancer Sciences, University of Manchester, Manchester, United Kingdom.ORCID 0000-0002-0192-7532
Jennie MorganDepartment of Gynaecological Oncology, Manchester University NHS Foundation Trust, Manchester, United Kingdom.ORCID 0000-0002-5757-8888
Cathrine HollandDepartment of Gynaecological Oncology, Manchester University NHS Foundation Trust, Manchester, United Kingdom.ORCID 0000-0002-6030-129X
Darren FlynnDepartment of Nursing, Midwifery and Health, University of Northumbria, Newcastle upon Tyne, United Kingdom.ORCID 0000-0001-7390-632X
Richard EdmondsonDivision of Cancer Sciences, University of Manchester, Manchester, United Kingdom.ORCID 0000-0003-2553-4423

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivePatients with advanced ovarian cancer face a range of treatment options, and there is unwarranted variation in treatment decision-making between UK providers. Decision support tools that produce data on treatment outcomes as a function of individual patient characteristics, would help both patients and clinicians to make informed, preference- and values-based choices. However, data on treatment outcomes to include in such tools are lacking.

methodsFollowing a literature review, a questionnaire was designed for use in a Delphi process to establish which treatment outcomes are important to both patients and clinicians in decision-making for treatment for advanced ovarian cancer. Patient and clinician panels were established.

resultsFollowing 2 Delphi rounds, consensus was achieved for 7/11 items in the patient panel and 8/11 items in the clinician panel. Consensus across both panels was achieved for inclusion of both overall survival and progression free survival as important items in the decision-making process, although there remained differences of opinion as to whether these should be presented as relative or absolute values.

conclusionInformation needs for treatment decision-making in ovarian cancer differ between and within patient and clinician groups. Whilst overall survival and progression free survival are universally accepted as important data items, decision support tools will need to be nuanced to allow presentation of a range of outcomes and associated probabilities, and in a range of formats, that can be tailored to the preferences of clinician and patients.

Indexed as

Delphi TechniqueOvarian NeoplasmsClinical Decision-MakingConsensusDecision Support TechniquesFemaleHumansPatient PreferenceProgression-Free SurvivalSurveys and QuestionnairesTreatment OutcomeUnited KingdomOvarian CancerPatient PreferenceShared Decision Making

Identifiers

PMID38576342
PMCPMC11390251

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.